Drug Interactions between Ibrance and Xgeva
This report displays the potential drug interactions for the following 2 drugs:
- Ibrance (palbociclib)
- Xgeva (denosumab)
Interactions between your drugs
Applies to: Xgeva (denosumab) and Ibrance (palbociclib)
Using denosumab together with palbociclib can increase the risk of serious infections involving the skin, lower stomach area (abdomen), bladder, ear, or inner lining of the heart. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Contact your doctor immediately if you develop fever or chills; red, swollen skin or skin that is hot or tender to the touch; itching or rash; blisters; severe abdominal pain; or frequent, urgent, or painful/burning urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
Applies to: Ibrance (palbociclib)
Palbociclib should be taken with food to help with its absorption. Do not consume grapefruit or grapefruit juice during treatment with palbociclib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of palbociclib. You may be more likely to experience side effects such as nausea; vomiting; diarrhea; loss of appetite; mouth sores; hair loss; weakness; pain, numbness, or tingling in the hands and feet; and impaired bone marrow function resulting in low numbers of different types of blood cells, which can increase the risk of anemia, bleeding problems, and infections. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.